2. Cancer
  3. Cancer Targeted Therapy

Cancer Targeted Therapy

Cancer targeted therapy is the foundation of precision medicine; it uses drugs or other substances to target specific genes and proteins that control cancer cells’ growth, division and spreading. Compared to traditional chemotherapy drugs, targeted-drugs can specifically act on cancer cells with high efficacy without damaging normal cells. Drugs used in cancer targeted therapy mainly includes small molecules and macromolecules (e.g., monoclonal antibodies), which can target cancer cells and constituents in the tumor microenvironment to activate the immune system. Anti-angiogenesis drugs, such as those targeting vascular endothelial growth factor (VEGF), epidermal growth factor receptor (EGFR), transforming growth factor (TGF)-α, TGF-β, Tumor necrosis factor (TNF)-α, and platelet-derived endothelial growth factor (PDGFR) inhibit the proliferation and metastasis of cancer cells. In recent years, the proportion of antibody drugs in cancer treatment has gradually become prominent. Antibody-drug conjugates (ADCs) are a new type of targeted drugs that are composed of monoclonal antibody, cytotoxic drug and linker. ADCs can deliver drugs to tumor cells and minimize the toxicity to normal tissues. Proteolysis-targeting chimera (PROTAC) is a useful technology for targeted protein degradation. PROTAC exploits the ubiquitin-proteasome system and forms a ternary complex with a hijacked E3 ubiquitin ligase and target protein, leading to polyubiquitination and degradation of the target protein.

Targeted therapy is a useful strategy in treatment of cancer either alone or in combination with standard chemotherapy. At present, targeted therapy has proved significant clinical success in the treatment of many types of cancer, including breast cancer, colorectal cancer, leukemia, ovarian cancer and lung cancer.

Cancer Targeted Therapy 관련 제품 (44300):

Cat. No. 상품명 CAS No. Purity 화학구조
  • HY-RI01999
    hsa-miR-6716-5p inhibitor
    hsa-miR-6716-5p inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
    hsa-miR-6716-5p inhibitor
  • HY-152648
    N6-Ethyl-2’-O-methyladenosine 157309-11-0
    N6-Ethyl-2’-O-methyladenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc.
    N6-Ethyl-2’-O-methyladenosine
  • HY-RI01694
    hsa-miR-548o-3p inhibitor
    hsa-miR-548o-3p inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
    hsa-miR-548o-3p inhibitor
  • HY-154052
    5′-Amino-2′,5′-dideoxyuridine 35959-38-7
    5′-Amino-2′,5′-dideoxyuridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc.
    5′-Amino-2′,5′-dideoxyuridine
  • HY-159593
    Ac-NH-(S,R,S)-AHPC-CO-cyclohexane-pyrimidine-diazabicyclo
    Ac-NH-(S,R,S)-AHPC-CO-cyclohexane-pyrimidine-diazabicyclo is an E3 Ligase Ligand-Linker Conjugate. Ac-NH-(S,R,S)-AHPC-CO-cyclohexane-pyrimidine-diazabicyclo can be used to synthesize PROTAC SMARCA2/4-degrader-1 (HY-159452).
    Ac-NH-(S,R,S)-AHPC-CO-cyclohexane-pyrimidine-diazabicyclo
  • HY-RI00805A
    hsa-miR-3689a-3p antagomir
    hsa-miR-3689a-3p antagomirs are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA antagomirs have 2 phosphorothioates at the 5' end, 4 phosphorothioates at the 3' end, 1 cholesterol group at the 3' end, and full-length nucleotide 2'-methoxy modification. The miRNA antagomirs strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning. Stability of miRNA antagomirs appears to be significantly higher than miRNA inhibitors, they exhibits enhanced cellular uptake, stability and regulatory activity in vivo.
    hsa-miR-3689a-3p antagomir
  • HY-135331S
    N-Desmethyl-Apalutamide-15N,d4
    N-Desmethyl-Apalutamide-15N,d4 is the 15N and deuterium labeled isotope of N-Desmethyl-Apalutamide (HY-135331). N-Desmethyl-Apalutamide, the major active metabolite of Apalutamide (HY-16060), is a selective competitive inhibitor of androgen receptor. N-Desmethyl-Apalutamide is catalyzed by CYP3A4 and CYP2C8 enzymes. The plasma protein binding rate of N-Desmethyl-Apalutamide reaches 95%, with albumin as the primary binding protein. N-Desmethyl-Apalutamide is suitable for prostate cancer-related research.
    N-Desmethyl-Apalutamide-<sup>15</sup>N,d<sub>4</sub>
  • HY-RI04330A
    rno-miR-299b-3p antagomir
    rno-miR-299b-3p antagomirs are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA antagomirs have 2 phosphorothioates at the 5' end, 4 phosphorothioates at the 3' end, 1 cholesterol group at the 3' end, and full-length nucleotide 2'-methoxy modification. The miRNA antagomirs strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning. Stability of miRNA antagomirs appears to be significantly higher than miRNA inhibitors, they exhibits enhanced cellular uptake, stability and regulatory activity in vivo.
    rno-miR-299b-3p antagomir
  • HY-154643
    9-(3-Deoxy-3-fluoro-β-D-ribofuranosyl)-9H-purin-2-amine 1612192-04-7
    9-(3-Deoxy-3-fluoro-β-D-ribofuranosyl)-9H-purin-2-amine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc.
    9-(3-Deoxy-3-fluoro-β-D-ribofuranosyl)-9H-purin-2-amine
  • HY-159605
    Autophagy inducer 5
    Autophagy inducer 5 (compound 21o) is a potent MCF-7 inhibitor (IC50: 2 μM), and a potential breast cancer inhibitor. Autophagy inducer 5 induces cellular autophagy by activating the ROS/JNK signaling pathway, which increases ROS generation and JNK phosphorylation, exerting cytotoxic effects.
    Autophagy inducer 5
  • HY-RI04270A
    rno-miR-193b-3p antagomir
    rno-miR-193b-3p antagomirs are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA antagomirs have 2 phosphorothioates at the 5' end, 4 phosphorothioates at the 3' end, 1 cholesterol group at the 3' end, and full-length nucleotide 2'-methoxy modification. The miRNA antagomirs strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning. Stability of miRNA antagomirs appears to be significantly higher than miRNA inhibitors, they exhibits enhanced cellular uptake, stability and regulatory activity in vivo.
    rno-miR-193b-3p antagomir
  • HY-RI03083
    mmu-miR-3544-3p inhibitor
    mmu-miR-3544-3p inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
    mmu-miR-3544-3p inhibitor
  • HY-R00001
    hsa-let-7a-2-3p mimic
    hsa-let-7a-2-3p mimics are small, chemically synthesized double-stranded RNAs that mimic endogenous miRNAs and enable miRNA functional analysis by up-regulation of miRNA activity.
    hsa-let-7a-2-3p mimic
  • HY-126997
    Bis-PEG3-PFP ester 1314378-13-6
    Bis-PEG3-PFP ester is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.
    Bis-PEG3-PFP ester
  • HY-13256AS1
    Desmethyl Erlotinib-d4-1 2012598-45-5
    Desmethyl Erlotinib-d4-1 (OSI-420-d4-1 (free base); CP-373420-d4-1) is deuterium-labeled Desmethyl Erlotinib (HY-13256A).
    Desmethyl Erlotinib-d<sub>4</sub>-1
  • HY-RI03116
    mmu-miR-378d inhibitor
    mmu-miR-378d inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
    mmu-miR-378d inhibitor
  • HY-169344
    CDK7-IN-31 2943043-62-5
    CDK7-IN-31 (compound 13) is a potent and orally active cyclin-dependent kinase 7 (CDK7) inhibitor with a Kd value of 0.18 nM. CDK7-IN-31 shows anticancer activity.
    CDK7-IN-31
  • HY-RI01725A
    hsa-miR-5579-5p antagomir
    hsa-miR-5579-5p antagomirs are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA antagomirs have 2 phosphorothioates at the 5' end, 4 phosphorothioates at the 3' end, 1 cholesterol group at the 3' end, and full-length nucleotide 2'-methoxy modification. The miRNA antagomirs strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning. Stability of miRNA antagomirs appears to be significantly higher than miRNA inhibitors, they exhibits enhanced cellular uptake, stability and regulatory activity in vivo.
    hsa-miR-5579-5p antagomir
  • HY-RI02420
    hsa-miR-7705 inhibitor
    hsa-miR-7705 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
    hsa-miR-7705 inhibitor
  • HY-178067
    Phthalimidinoglutarimide-5-piperazine-COC2-alkynes
    Phthalimidinoglutarimide-5-piperazine-COC2-alkynes is a synthesized E3 ligase ligand-linker conjugate that can be used to synthesize PROTAC BCL-xL/BCL-w Degrader 1 (HY-178066). PROTAC BCL-xL/BCL-w Degrader 1 is a potent BCL-xL/BCL-w PROTAC degrader with anti-cancer activity.
    Phthalimidinoglutarimide-5-piperazine-COC2-alkynes